Royce & Associates LP Has $805,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Key Points

• Royce & Associates LP increased its holdings in Supernus Pharmaceuticals by 90.0% during Q1, owning 24,582 shares worth approximately $805,000.
• Several other hedge funds made significant moves related to Supernus Pharmaceuticals, with one firm increasing its stake by 6,931.3% during the same period.
• On July 20th, Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating.

Royce & Associates LP raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 90.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,582 shares of the specialty pharmaceutical company's stock after acquiring an additional 11,644 shares during the quarter. Royce & Associates LP's holdings in Supernus Pharmaceuticals were worth $805,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after acquiring an additional 1,083 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in Supernus Pharmaceuticals by 14.7% in the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after acquiring an additional 1,000 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Supernus Pharmaceuticals by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after acquiring an additional 9,590 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in Supernus Pharmaceuticals by 6.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after acquiring an additional 3,495 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Supernus Pharmaceuticals by 63.6% during the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after buying an additional 6,867 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, July 20th. Cantor Fitzgerald raised shares of Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $42.00 price objective for the company in a research note on Wednesday.

Supernus Pharmaceuticals Trading Up 1.1%

SUPN stock traded up $0.40 during mid-day trading on Friday, reaching $35.50. 305,779 shares of the stock traded hands, compared to its average volume of 586,535. Supernus Pharmaceuticals, Inc. has a 52-week low of $27.05 and a 52-week high of $40.28. The company has a market cap of $1.99 billion, a P/E ratio of 31.97 and a beta of 0.70. The stock's fifty day moving average is $32.57 and its 200-day moving average is $33.42.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.